Literature DB >> 16999435

Substituent effects on Gd(III)-based MRI contrast agents: optimizing the stability and selectivity of the complex and the number of coordinated water molecules.

Valérie C Pierre1, Mauro Botta, Silvio Aime, Kenneth N Raymond.   

Abstract

Hydroxypyridinone (HOPO)-based Gd(III) complexes have previously been shown to exhibit high relaxivity, especially at the high magnetic fields that are clinically relevant for present and future clinical use. This is due to more than one coordinated water molecule exchanging rapidly with bulk solvent. These complexes, however, present poor water solubility. Heteropodal complexes which include a terephthalamide (TAM) moiety maintain the high relaxivity characteristics of the HOPO family and have been functionalized with solubilizing substituents of various charges. The charge of the substituent significantly affects the stability of the Gd(III) complex, with the most stable complex presenting a neutral charge. The solubilizing substituent also moderately affects the affinity of the complex for physiological anions, with the highest affinity observed for the positively charged complex. In any case, only two anions, phosphate and oxalate, measureably bind the Gd(III) complex with weak affinities that are comparable to other q = 1 complexes and much weaker than DO3A, q = 2 based complexes. Furthermore, unlike poly(amino-carboxylate)-based complexes, HOPO-based Gd(III) complexes do not show any noticeable interaction with carbonates. The nature of the substituent can also favorably stabilize the coordination of a third water molecule on the Gd(III) center and lead to a nine-coordinate ground state. Such complexes that attain q = 3 incorporate a substituent beta to the terminal amide of the TAM podand that is a hydrogen-bond acceptor, suggesting that the third water molecule is coordinated to the metal center through a hydrogen-bond network. These substituents include alcohols, primary amines, and acids. Moreover, the coordination of a third water molecule has been achieved without destabilizing the complex.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16999435      PMCID: PMC3190981          DOI: 10.1021/ic061262q

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  22 in total

1.  Controlling the variation of axial water exchange rates in macrocyclic lanthanide(III) complexes.

Authors:  Silvio Aime; Alessandro Barge; Andrei S Batsanov; Mauro Botta; Daniela Delli Castelli; Franco Fedeli; Armando Mortillaro; David Parker; Horst Puschmann
Journal:  Chem Commun (Camb)       Date:  2002-05-21       Impact factor: 6.222

2.  The relationship between thermodynamics and the toxicity of gadolinium complexes.

Authors:  W P Cacheris; S C Quay; S M Rocklage
Journal:  Magn Reson Imaging       Date:  1990       Impact factor: 2.546

Review 3.  Next generation, high relaxivity gadolinium MRI agents.

Authors:  Kenneth N Raymond; Valérie C Pierre
Journal:  Bioconjug Chem       Date:  2005 Jan-Feb       Impact factor: 4.774

4.  Syntheses and relaxation properties of mixed gadolinium hydroxypyridinonate MRI contrast agents.

Authors:  S M Cohen; J Xu; E Radkov; K N Raymond; M Botta; A Barge; S Aime
Journal:  Inorg Chem       Date:  2000-12-11       Impact factor: 5.165

5.  The highest water exchange rate ever measured for a Gd(III) chelate.

Authors:  Marta Mato-Iglesias; Carlos Platas-Iglesias; Kristina Djanashvili; Joop A Peters; Eva Tóth; Edina Balogh; Robert N Muller; Luce Vander Elst; Andrés de Blas; Teresa Rodríguez-Blas
Journal:  Chem Commun (Camb)       Date:  2005-08-26       Impact factor: 6.222

6.  Toward optimized high-relaxivity MRI agents: thermodynamic selectivity of hydroxypyridonate/catecholate ligands.

Authors:  Valérie C Pierre; Marco Melchior; Dan M J Doble; Kenneth N Raymond
Journal:  Inorg Chem       Date:  2004-12-27       Impact factor: 5.165

7.  Hetero-tripodal hydroxypyridonate gadolinium complexes: syntheses, relaxometric properties, water exchange dynamics, and human serum albumin binding.

Authors:  Marlon K Thompson; Dan M J Doble; Luke S Tso; Serena Barra; Mauro Botta; Silvio Aime; Kenneth N Raymond
Journal:  Inorg Chem       Date:  2004-12-27       Impact factor: 5.165

8.  Fe(III)-templated Gd(III) self-assemblies-a new route toward macromolecular MRI contrast agents.

Authors:  Valérie C Pierre; Mauro Botta; Silvio Aime; Kenneth N Raymond
Journal:  J Am Chem Soc       Date:  2006-07-26       Impact factor: 15.419

9.  Toward optimized high-relaxivity MRI agents: the effect of ligand basicity on the thermodynamic stability of hexadentate hydroxypyridonate/catecholate gadolinium(III) complexes.

Authors:  Dan M J Doble; Marco Melchior; Brendon O'Sullivan; Carsten Siering; Jide Xu; Valérie C Pierre; Kenneth N Raymond
Journal:  Inorg Chem       Date:  2003-08-11       Impact factor: 5.165

10.  NMR relaxometric study of new Gd(III) macrocyclic complexes and their interaction with human serum albumin.

Authors:  Mauro Botta; Silvio Quici; Gianluca Pozzi; Giovanni Marzanni; Roberto Pagliarin; Serena Barra; Simonetta Geninatti Crich
Journal:  Org Biomol Chem       Date:  2004-01-21       Impact factor: 3.876

View more
  27 in total

1.  Strategies for the preparation of bifunctional gadolinium(III) chelators.

Authors:  Luca Frullano; Peter Caravan
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

2.  Eu(III) complexes of functionalized octadentate 1-hydroxypyridin-2-ones: stability, bioconjugation, and luminescence resonance energy transfer studies.

Authors:  Evan G Moore; Jide Xu; Christoph J Jocher; Todd M Corneillie; Kenneth N Raymond
Journal:  Inorg Chem       Date:  2010-11-01       Impact factor: 5.165

3.  Synthesis and Characterization of Ln(III) Complexes and its Luminescence Properties.

Authors:  Jashobanta Sahoo; P S Subramanian; Santlal Jaiswar
Journal:  J Fluoresc       Date:  2016-05-24       Impact factor: 2.217

4.  1-Methyl-3-hydroxy-pyridin-2-one complexes of near infra-red emitting lanthanides: efficient sensitization of Yb(III) and Nd(III) in aqueous solution.

Authors:  Evan G Moore; Jide Xu; Sheel C Dodani; Christoph J Jocher; Anthony D'Aléo; Michael Seitz; Kenneth N Raymond
Journal:  Inorg Chem       Date:  2010-05-03       Impact factor: 5.165

5.  Improving T₁ and T₂ magnetic resonance imaging contrast agents through the conjugation of an esteramide dendrimer to high-water-coordination Gd(III) hydroxypyridinone complexes.

Authors:  Piper J Klemm; William C Floyd; Danil E Smiles; Jean M J Fréchet; Kenneth N Raymond
Journal:  Contrast Media Mol Imaging       Date:  2012 Jan-Feb       Impact factor: 3.161

6.  Analysis of Lanthanide Complex Dendrimer Conjugates for Bimodal NIR and MRI Imaging.

Authors:  Christopher M Andolina; Piper J Klemm; William C Floyd; Jean M J Fréchet; Kenneth N Raymond
Journal:  Macromolecules       Date:  2012-11-12       Impact factor: 5.985

7.  Modulating water-exchange rates of lanthanide(III)-containing polyaminopolycarboxylate-type complexes using polyethylene glycol.

Authors:  Buddhima N Siriwardena-Mahanama; Matthew J Allen
Journal:  Dalton Trans       Date:  2013-05-21       Impact factor: 4.390

8.  Conjugation to Biocompatible Dendrimers Increases Lanthanide T2 Relaxivity of Hydroxypyridinone (HOPO) Complexes for Magnetic Resonance Imaging (MRI).

Authors:  Piper J Klemm; William C Floyd; Christopher M Andolina; Jean M J Fréchet; Kenneth N Raymond
Journal:  Eur J Inorg Chem       Date:  2012-04       Impact factor: 2.524

9.  Effect of a mesitylene-based ligand cap on the relaxometric properties of Gd(III) hydroxypyridonate MRI contrast agents.

Authors:  Eric J Werner; Mauro Botta; Silvio Aime; Kenneth N Raymond
Journal:  Contrast Media Mol Imaging       Date:  2009 Sep-Oct       Impact factor: 3.161

10.  Optimized relaxivity and stability of [Gd(H(2,2)-1,2-HOPO)(H2O)]- for use as an MRI contrast agent.

Authors:  Christoph J Jocher; Mauro Botta; Stefano Avedano; Evan G Moore; Jide Xu; Silvio Aime; Kenneth N Raymond
Journal:  Inorg Chem       Date:  2007-05-11       Impact factor: 5.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.